Wcn26-9116 Efficacy of Pegcetacoplan in Patients With Lower Baseline Proteinuria: A Subgroup Analysis From the Valiant Trial
Key Result
Pegcetacoplan treatment for 52 weeks demonstrated consistent clinical efficacy and sustained benefit in adolescents, matching the overall VALIANT trial population.
Key Points
The study aims to evaluate the efficacy of pegcetacoplan in patients with lower baseline proteinuria.
Conducted a subgroup analysis from the VALIANT trial.
Evaluated clinical efficacy over a 52-week treatment period.
Included adolescents as a specific focus group.
Efficacy of pegcetacoplan was consistent with the overall VALIANT population.
Demonstrated sustained benefits over 52 weeks in treated adolescents.
Structured PICO
Does pegcetacoplan reduce proteinuria in patients with C3G and IC-MPGN with lower baseline proteinuria?
P
Population
Patients with C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) with baseline proteinuria ≤1.5 g/g
Change from baseline to Week 26 in log-transformed urine protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR)surrogate
Pegcetacoplan demonstrated clinically meaningful reductions in proteinuria in patients with C3G and IC-MPGN with lower baseline proteinuria (≤1.5 g/g).
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
Conclusion: Clinical efficacy of 52 weeks of pegcetacoplan treatment for adolescents was consistent with the overall population of VALIANT, confirming its sustained benefit in broad patient populations.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Cite This Study
Han et al. (Wed,) reported a other. Pegcetacoplan treatment for 52 weeks demonstrated consistent clinical efficacy and sustained benefit in adolescents, matching the overall VALIANT trial population.